| First Author | Brannan JM | Year | 2015 |
| Journal | J Infect Dis | Volume | 212 Suppl 2 |
| Pages | S282-94 | PubMed ID | 25943199 |
| Mgi Jnum | J:350760 | Mgi Id | MGI:7664210 |
| Doi | 10.1093/infdis/jiv215 | Citation | Brannan JM, et al. (2015) Interferon alpha/beta Receptor-Deficient Mice as a Model for Ebola Virus Disease. J Infect Dis 212 Suppl 2:S282-94 |
| abstractText | A major obstacle in ebolavirus research is the lack of a small-animal model for Sudan virus (SUDV), as well as other wild-type (WT) ebolaviruses. Here, we expand on research by Bray and by Lever et al suggesting that WT ebolaviruses are pathogenic in mice deficient for the type 1 interferon (IFN) alpha/beta receptor (IFNalpha/betaR-/-). We examined the disease course of several WT ebolaviruses: Boneface (SUDV/Bon) and Gulu variants of SUDV, Ebola virus (EBOV), Bundibugyo virus (BDBV), Tai Forest virus, and Reston virus (RESTV). We determined that exposure to WT SUDV or EBOV results in reproducible signs of disease in IFNalpha/betaR-/- mice, as measured by weight loss and partial lethality. Vaccination with the SUDV or EBOV glycoprotein (GP)-expressing Venezuelan equine encephalitis viral replicon particle vaccine protected these mice from SUDV/Bon and EBOV challenge, respectively. Treatment with SUDV- or EBOV-specific anti-GP antibodies protected mice from challenge when delivered 1-3 days after infection. Serial sampling experiments revealed evidence of disseminated intravascular coagulation in the livers of mice infected with the Boneface variant of SUDV, EBOV, and BDBV. Taken together, these data solidify the IFNalpha/betaR-/- mouse as an important and useful model for the study of WT EBOV disease. |
